Variable | Adjusted HR (95% CI) | P-value | |
---|---|---|---|
Sex | Male vs Female | 0.90 (0.57-1.42) | >0.05 |
Address | Rural vs Urban | 0.98 (0.46-2.05) | >0.05 |
Phase of enrolment | Early phase | 1.36 (0.78-2.37) | >0.05 |
Rapid scale-up | 1.09 (0.59-2.00) | >0.05 | |
Recent phase* | 1.00 | ||
Age group | 0-4 years | 0.50 (0.25-0.97) | 0.04 |
5-9 years | 0.40 (0.42-1.41) | >0.05 | |
10-14 years* | 1.00 | ||
WHO clinical stage | Stage I | 0.27 (0.09-0.80) | 0.02 |
Stage II | 0.69 (0.27-1.71) | >0.05 | |
Stage III | 0.88 (0.38-2.04) | >0.05 | |
Stage IV* | 1.00 |